EV71

SINOVAC Reports Unaudited Second Half of 2023 Financial Results and Files 2023 Annual Report on Form 20-F

Retrieved on: 
月曜日, 4月 29, 2024
Biotechnology, General Health, Infectious Diseases, Health, Pharmaceutical, Heng, NMPA, The Twelve Months, Vaccine, Enterovirus, District court, Court, GAAP, Person, EV71, WHO, Hearing, National Medical Products Administration, Hand, Exchange, Complaint, Sinovac Biotech, Privy council, Good, Annual report, Influenza, Infection, OrbiMed, Motion, Foot, Judgement, Rights, GMP, Clinical trial, Government, Appellate court, Medication, Capital, Ageing, Influenza vaccine, Cancer, Trust, Bank statement, HFMD, COVID-19, Growth, Hepatitis

The Company also reported its unaudited financial results for the second half and audited financial for the full year ended December 31, 2023.

Key Points: 
  • The Company also reported its unaudited financial results for the second half and audited financial for the full year ended December 31, 2023.
  • Sales for the second half of 2023 were $307.9 million, compared to $280.5 million in the prior year period.
  • R&D expenses in the second half of 2023 were $193.4 million, compared to $257.7 million in the prior year period.
  • The Company’s financial statements for the second half of 2023 are prepared and presented in accordance with U.S. GAAP.

Clover Announces Corporate Updates and Full Year 2022 Financial Results

Retrieved on: 
水曜日, 3月 29, 2023
EUA, Vaccine, GMP, SCB-2019, Cold medicine, Omicron, EU, Technology transfer, Clinical trial, International, Vaccination, The Post-Pandemic World Order, SARS-CoV-2, DPT vaccine, COVID-19, G&A, Diphtheria, Research, EV71, Respiratory syncytial virus, Influenza, CDMO, COVID-19 vaccine, RSV, International Financial Reporting Standards, Tetanus, Growth, Ageing, CpG, Immunodeficiency, Commercial, Health, Cross-promotion, Pharmaceutical industry, Cryptocurrency, Clover

SHANGHAI, China, March 29, 2023 (GLOBE NEWSWIRE) -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced corporate updates and financial results for the year ended December 31, 2022.

Key Points: 
  • (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced corporate updates and financial results for the year ended December 31, 2022.
  • Comprehensive Global Vaccine Development: Clinical trial results released and published in 2022 consistently demonstrated that SCB-2019 elicited broad cross-neutralization across variants.
  • Notably, in January 2022, Clover published the final efficacy results from its global Phase 2/3 study of SCB-2019 in The Lancet.
  • Clover also announced positive data from its Phase 3 study evaluating SCB-2019 as a heterologous COVID-19 booster vaccine.

Clover Provides Updates on COVID-19 Vaccine Commercial Launch and Strategic Priorities in 2023

Retrieved on: 
月曜日, 1月 16, 2023
Hospital, World Health Organization, Foot, Severe acute respiratory syndrome coronavirus 2, Pediatrics, SCB-2019, Commercial, COVID-19 vaccine, Oral and maxillofacial pathology, EUA, Death, Vaccination, Environment, Health, Research, Whooping cough, EMA, GMP, Development, WHO, Diphtheria, CAS-1, European Medicines Agency, RSV, Co-promotion, G&A, COVID-19, CpG, Safety, Respiratory syncytial virus, Vaccine, RMB, Omicron, Tetanus, EV71, DPT vaccine, Immunity, Pharmaceutical industry, Fine chemical, Risk management, Hand, Clover

SHANGHAI, China, Jan. 15, 2023 (GLOBE NEWSWIRE) -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today provided updates on the commercialization of SCB-2019 (CpG 1018/Alum) in China and strategic priorities in 2023.

Key Points: 
  • Commercial Launch Expected to Begin in Q1 2023: Clover has started commercial launch preparation activities in multiple key provinces and municipalities, based on Clover’s evaluation of market dynamics (including factors such as strategic fit, population size and competitive environment).
  • To date, Clover has received robust interest and demand based on the premium product profile of SCB-2019 and expects the commercial launch in these strategically prioritized areas to begin in Q1 2023.
  • At Least One In-Licensing Deal in H1 2023: At least one mid- to late-stage vaccine in-licensing deal announcement is expected in H1 2023.
  • SCB-2019: Concurrent with its commercial launch in China, Clover plans to conduct real-world effectiveness studies, with data potentially available in H2 2023.

IQAir Launches Smart Slim Bionic Air Purifier Atem X

Retrieved on: 
火曜日, 11月 29, 2022
Smoke, Ministry of Education (Malaysia), Allergen, Heart, Organization, EV71, Escherichia coli, H1N1, Bacteria, Atem, Aspergillus niger, CADR, Patent, Noise, City, Virus, Atmosphere, CO2, Influenza A virus, Slim, IQAir, Heating, ventilation, and air conditioning, Mobile phone

LA MIRADA, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) -- IQAir, the Swiss air quality technology expert, in anticipation of its 60th anniversary, introduces Atem X , a smart, slim, bionic air purifier.

Key Points: 
  • LA MIRADA, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) -- IQAir, the Swiss air quality technology expert, in anticipation of its 60th anniversary, introduces Atem X , a smart, slim, bionic air purifier.
  • Atem X uses patented and patent pending technologies to increase air cleaning performance, while reducing noise, energy consumption and the overall size of the air purifier.
  • Flexible Air Rotation technology allows Atem X to maximize air cleaning regardless of the position of the air purifier or the shape or size of the room.
  • Smart app integration: Atem X can be remotely controlled and provides advanced air quality data and usage statistics via the IQAir AirVisual air quality app.

IQAIR LAUNCHES SMART SLIM BIONIC AIR PURIFIER ATEM X

Retrieved on: 
火曜日, 11月 15, 2022
Smoke, CADR, Slim, Allergen, Heart, City, Ministry of Education (Malaysia), Organization, CO2, H1N1, EV71, Influenza A virus, Escherichia coli, Bacteria, Patent, Atem, Virus, Aspergillus niger, IQAir, Atmosphere, Noise, Heating, ventilation, and air conditioning, Mobile phone

LA MIRADA, Calif., Nov. 15, 2022 /PRNewswire/ -- IQAir, the Swiss air quality technology expert, in anticipation of its 60th anniversary, introduces Atem X, a smart, slim, bionic air purifier.

Key Points: 
  • LA MIRADA, Calif., Nov. 15, 2022 /PRNewswire/ -- IQAir, the Swiss air quality technology expert, in anticipation of its 60th anniversary, introduces Atem X, a smart, slim, bionic air purifier.
  • Flexible Air Rotation technology allows Atem X to maximize air cleaning regardless of the position of the air purifier or the shape or size of the room.
  • Smart app integration: Atem X can be remotely controlled and provides advanced air quality data and usage statistics via the IQAir AirVisual air quality app.
  • Atem X is available in two configurations: Atem X and Atem X Pro.

SINOVAC Varicella Vaccine Prequalified by WHO

Retrieved on: 
金曜日, 11月 4, 2022
Health, Infectious Diseases, COVID-19, Clinical Trials, Pharmaceutical, Biotechnology, Company, Mumps, Polio, III, World, Influenza A virus subtype H1N1, World Health Organization, WHO, Foot-and-mouth disease virus, Hepatitis A, Vaccine, COVID-19, H5N1, CEO, National TB Elimination Program (India), Chickenpox, Seroconversion, HFMD, Oka, NASDAQ, Infection, R, Streptococcus, EV71, Program, Sinovac Biotech

This marks the first WHO prequalified Chinese varicella vaccine and the fourth SINOVAC vaccine to receive WHO approval.

Key Points: 
  • This marks the first WHO prequalified Chinese varicella vaccine and the fourth SINOVAC vaccine to receive WHO approval.
  • Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, Now that SINOVAC has received WHO prequalification for our varicella vaccine, we can provide a new weapon for prevention and control of infectious diseases globally.
  • Previously, three other vaccines by SINOVAC were also approved by WHO in various uses and conditions, including Healive (the hepatitis A vaccine), CoronaVac (the COVID-19 vaccine) and the Sabin-strain inactivated polio vaccine.
  • In 2022, SINOVACs Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.

SINOVAC to Showcase Products at CPHI Frankfurt

Retrieved on: 
金曜日, 10月 28, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, R, Chickenpox, Company, Influenza A virus subtype H1N1, Mumps, NASDAQ, Polio, H5N1, Vaccine, Pyaar Tune Kya Kiya (TV series), Foot-and-mouth disease virus, Booth, EV71, Streptococcus, Program, COVID-19, Infection, HFMD, Hepatitis A, WHO, Sinovac Biotech, Fine chemical

Sinovac Biotech Ltd. (SINOVAC or the Company) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Company will participate in CPHI Frankfurt, one of the worlds largest pharmaceutical exhibitions, from 1st to 3rd of November, in Frankfurt, Germany.

Key Points: 
  • Sinovac Biotech Ltd. (SINOVAC or the Company) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Company will participate in CPHI Frankfurt, one of the worlds largest pharmaceutical exhibitions, from 1st to 3rd of November, in Frankfurt, Germany.
  • At Booth#41G20, the first floor of Hall 4, Messe Frankfurt, SINOVAC will greet all visitors of CPHI and present its comprehensive portfolio.
  • Helen Yang, Chief Business Officer of SINOVAC said, SINOVAC is an old friend of CPHI, and we are happy to finally return to CPHIs in-person event for the first time since the outbreak of the COVID-19 pandemic globally.
  • SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities.

SINOVAC Approved to Initiate Clinical Trial for Its Omicron Containing COVID-19 Vaccine in Chile

Retrieved on: 
火曜日, 9月 6, 2022
Research, Infectious Diseases, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Valence (chemistry), COVID-19, CEO, Safety, Program, Influenza A virus subtype H1N1, WHO, NASDAQ, Vaccine, Streptococcus, R, Infection, H5N1, Instituto Butantan, HFMD, Polio, Chickenpox, Hepatitis A, Mumps, ISP, Company, Foot-and-mouth disease virus, RNA transfection, Clinical trial, Delta, EV71, Sinovac Biotech, Omicron

In this phase II randomized, double-blind, multicenter clinical trial, 826 fully vaccinated adults will be recruited.

Key Points: 
  • In this phase II randomized, double-blind, multicenter clinical trial, 826 fully vaccinated adults will be recruited.
  • Mr. Weidong Yin, the Chairman, President, and CEO of SINOVAC said, SINOVAC has made great progress collaborating with global partners in the development and manufacturing of the COVID-19 vaccine.
  • Its COVID-19 vaccine, CoronaVac, has been approved for use in more than 60 countries and regions worldwide.
  • SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities.

SINOVAC COVID-19 Vaccine Approved for Use in Children Above 6 months of Age in Hong Kong

Retrieved on: 
水曜日, 8月 3, 2022
Biotechnology, Pharmaceutical, General Health, Health, COVID-19, Children, Infectious Diseases, Consumer, NASDAQ, Vaccine, Safety, Foot-and-mouth disease virus, Minor, Department, R, Program, Center, Health Bureau, H5N1, WHO, Scientific Committee on Antarctic Research, Infection, HFMD, Sinovac Biotech, Mumps, III, Scientific Committee on Emerging and Newly Identified Health Risks, Polio, Chickenpox, Hepatitis A, COVID-19, CoronaVac, Company, EV71, Carrie Lam as Chief Executive of Hong Kong, Vaccination, Streptococcus, COVID-19 vaccine, Ageing, Zoonosis, Influenza A virus subtype H1N1, Government

The vaccination schedule for this age group follows the same vaccination schedule of older children.

Key Points: 
  • The vaccination schedule for this age group follows the same vaccination schedule of older children.
  • SINOVAC initiated its COVID-19 vaccine (CoronaVac) phase III clinical studies among children aged 6 months to 17 years since 2021.
  • Preliminary results show the vaccine has a good safety and immunogenicity profile, with no severe adverse reaction reported 6 months after two doses of vaccination among children aged 6 months to 35 months.
  • SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities.

SINOVAC Initiates Clinical Trial for Its Quadrivalent Influenza Vaccine in Chile

Retrieved on: 
火曜日, 7月 19, 2022
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, Clinical Trials, Influenza A virus subtype H1N1, III, Chickenpox, Volunteering, Infection, WHO, Safety, Republic, Polio, Foot-and-mouth disease virus, Program, EV71, PI, NASDAQ, Sinovac Biotech, COVID-19, Company, Hepatitis A, Ageing, Mumps, Streptococcus, H5N1, Vaccine, Clinical trial, HFMD, R, Coro de la Pontificia Universidad Católica de Puerto Rico

This clinical trial aims to evaluate the immunogenicity and safety of the quadrivalent influenza vaccine among individuals aged 3 and above.

Key Points: 
  • This clinical trial aims to evaluate the immunogenicity and safety of the quadrivalent influenza vaccine among individuals aged 3 and above.
  • In total, there will be 1,600 volunteers recruited, half of whom will receive 1 dose of SINOVACs inactivated quadrivalent influenza vaccine, and the other half will receive a different quadrivalent influenza vaccine commercially available in Chile.
  • Children aged between 3 and 8 of both groups who havent received any influenza vaccine will receive 2 doses of influenza vaccine.
  • The upcoming clinical trial in Chile will provide further evidence on the efficacy and safety of SINOVACs quadrivalent influenza vaccine.